Sartorius AGXTER:SRT3 +3.15%83 OCF Margin % is 21.01% as of Mar. 2026, which is 1% below its 10-year median of 21.28. GuruFocus rates XTER:SRT3 with a GF Score™ of 83/100 and a GF Value™ of €256.36 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Sartorius AG ranks better than 88.1% on this metric.
The historical rank and industry rank for Sartorius AG's OCF Margin % or its related term are showing as below:
XTER:SRT3'
s OCF Margin % Range Over the Past 10 Years
Min: 13.11 Med: 21.28 Max: 28.88
Current: 24.95
During the past 13 years, the highest OCF Margin % of Sartorius AG was 28.88%. The lowest was 13.11%. And the median was 21.28%.
XTER:SRT3's OCF Margin % is ranked better than 88.1% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs XTER:SRT3: 24.95
Sartorius AG OCF Margin % Related Terms
Sartorius AG OCF Margin % Historical Data
* Premium members only.
The historical data trend for Sartorius AG's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:SRT3 vs ISRG, BDX, MDLN: OCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius AG's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (XTER:SRT3) has a OCF Margin % of 21.01% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sartorius AG and its competitors. This is near median its historical median of 21.28. Over the past decade, Sartorius AG's OCF Margin % has ranged from 13.11 to 28.88. According to the industry distribution chart, Sartorius AG ranks #97 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 11.9%.
Is Sartorius AG's OCF Margin % too high?
Sartorius AG's current OCF Margin % of 21.01% is near median its 10-year median of 21.28. Over the past 10 years, this metric has ranged from a low of 13.11 to a high of 28.88. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Sartorius AG's value of 21.01% is 258.5% above this industry median. Based on the distribution chart, Sartorius AG ranks #97 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius AG has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's OCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #97 out of 815 companies for OCF Margin %. This places Sartorius AG in the top 12% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.86. Sartorius AG's value of 21.01% is 258.5% above this benchmark. Historically, Sartorius AG's own OCF Margin % has ranged from 13.11 to 28.88 over the past decade. While the company's 10-year median is 21.28 vs. the industry median of 5.86, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current OCF Margin % of 21.01% is 258.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current OCF Margin % is 21.01%, which is near median its own 10-year median of 21.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (XTER:SRT3) is currently considered Modestly Undervalued. The stock's GF Value™ is €256.36, compared to a current price of €219.40 — trading 14.4% below its estimated fair value. The current OCF Margin % is 21.01%, which is near median its 10-year median of 21.28 and 258.5% above the Medical Devices & Instruments industry median of 5.86. Sartorius AG's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sartorius AG (XTER:SRT3), the current OCF Margin % is 21.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (XTER:SRT3) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of €219.40 is trading 14.4% below its estimated GF Value™ of €256.36.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for XTER:SRT3:
OCF Margin %: 21.01% (near median its 10-year median of 21.28)
GF Value™: €256.36 vs. price of €219.40 (14.4% below fair value)
Industry Position: 258.5% above the Medical Devices & Instruments median (#97 of 815)
No single metric tells the full story. See the XTER:SRT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
83GF Score
Get the complete analysis for XTER:SRT3
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:SRT3 has been successfully added to your 
